# A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

> **NCT01121640** · NA · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 854 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **PROCEDURE:** CA125 assay on Abbott Architect i1000SR platform
- **PROCEDURE:** HE4 assay on Architect i1000SR platform
- **PROCEDURE:** Transvaginal Ultrasound

## Key facts

- **NCT ID:** NCT01121640
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2015-05-07
- **Final completion:** 2015-05-07
- **Target enrollment:** 854 (ACTUAL)
- **Last updated:** 2018-12-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121640, "A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01121640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*